ArticleCancer diagnosis & prognosis
The Role of p300 and TMPRSS2 in Prostate Cancer: Immunohistochemical Perspectives and Gleason Correlations.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Transmembrane protease, serine 2 (TMPRSS2), and E1A-associated protein (p300) are important factors in prostate cancer (PCa) pathogenesis, playing significant roles in androgen receptor (AR) signaling and tumor progression. Despite their established role in PCa biology, their immunohistochemical alterations across different Gleason patterns and histological grades remain unclear. This experimental study aimed to assess TMPRSS2 and p300 expression in non-malignant and cancerous prostate tissues, correlating their localization and intensity with Gleason scores and tumor aggressiveness. Materials and Methods: A total of 58 paraffin-embedded prostate adenocarcinoma (PRAD) tissue sections from male patients who underwent radical prostatectomy, including low- and high-grade tumors and high-grade prostatic intraepithelial neoplasia (HGPIN), were analyzed. Immunohistochemistry (IHC) for TMPRSS2 and p300 was performed. Two independent pathologists conducted H-score assessments with complete interobserver concordance, evaluating staining intensity, localization, and expression patterns, correlating findings with Gleason scores and cancer stage. Results: TMPRSS2 and p300 exhibited variable expression levels across all tissue samples. While TMPRSS2 expression increased in aggressive tumors, its staining intensity did not change significantly across different Gleason grades. p300 over-expression was significantly associated with aggressive tumors, particularly Gleason pattern 5 (p=0.011). High-grade tumors [Gleason ≥7(4+3)] demonstrated higher p300 expression compared to low-grade tumors [Gleason ≤7(3+4)], with minimal staining observed in Gleason score 6. Conclusion: Expression patterns of TMPRSS2 and p300 correlate with PCa aggressiveness. These findings support the growing evidence suggesting their potential role as prognostic markers and therapeutic targets. The implementation of well-designed studies on a larger scale is of utmost importance, to draw safer conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.